2021
DOI: 10.1186/s12888-020-02992-4
|View full text |Cite
|
Sign up to set email alerts
|

Study protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle in antipsychotic users (MELIA) trial

Abstract: Background Antipsychotic-induced Weight Gain (AiWG) is a debilitating and common adverse effect of antipsychotics. AiWG negatively impacts life expectancy, quality of life, treatment adherence, likelihood of developing type-2 diabetes and readmission. Treatment of AiWG is currently challenging, and there is no consensus on the optimal management strategy. In this study, we aim to evaluate the use of metformin for the treatment of AiWG by comparing metformin with placebo in those receiving treat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(3 citation statements)
references
References 41 publications
(56 reference statements)
0
3
0
Order By: Relevance
“…All but one patient lost weight including 96% of those who were taking antipsychotics, and nearly half achieved clinically significant weight loss [defined as ≥5% reduction in body weight ( 34 )]. This welcome outcome alone makes a compelling case for the implementation of the KD in people who are taking antipsychotic medications, whether or not psychiatric symptoms improve in response to the KD, as counteracting antipsychotic-induced weight gain is extremely difficult ( 63 ).…”
Section: Discussionmentioning
confidence: 99%
“…All but one patient lost weight including 96% of those who were taking antipsychotics, and nearly half achieved clinically significant weight loss [defined as ≥5% reduction in body weight ( 34 )]. This welcome outcome alone makes a compelling case for the implementation of the KD in people who are taking antipsychotic medications, whether or not psychiatric symptoms improve in response to the KD, as counteracting antipsychotic-induced weight gain is extremely difficult ( 63 ).…”
Section: Discussionmentioning
confidence: 99%
“…All but one patient lost weight including 96% of those who were taking antipsychotics, and nearly half achieved clinically significant weight loss [defined as ≥5% reduction in body weight (34)]. This welcome outcome alone makes a compelling case for the implementation of the KD in people who are taking antipsychotic medications, whether or not psychiatric symptoms improve in response to the KD, as counteracting antipsychoticinduced weight gain is extremely difficult (63).…”
Section: Strengths and Limitationsmentioning
confidence: 99%
“…All but one patient lost weight including 96% of those who were taking antipsychotics, and nearly half achieved clinically significant weight loss [defined as ≥5% reduction in body weight (34)]. This welcome outcome alone makes a compelling case for the implementation of the KD in people who are taking antipsychotic medications, whether or not psychiatric symptoms improve in response to the KD, as counteracting antipsychoticinduced weight gain is extremely difficult (63).…”
Section: Strengths and Limitationsmentioning
confidence: 99%